Other
Depreciation
Neurocrine Biosciences Depreciation increased by 12.5% to $7.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $6.60M to $7.20M. Over 4 years (FY 2021 to FY 2025), Depreciation shows an upward trend with a 24.3% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
High depreciation relative to revenue may indicate a capital-intensive business model or significant recent investment in infrastructure.
Detailed definition
The systematic allocation of the cost of tangible assets over their useful lives. This non-cash expense reflects the wea...
Peer comparison
Standard accounting metric across all capital-intensive industries.
Metric ID:
other_depreciationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.60M | $2.80M | $3.00M | $3.30M | $3.90M | $4.00M | $3.90M | $4.10M | $4.20M | $4.60M | $4.90M | $5.30M | $6.40M | $5.60M | $6.20M | $6.60M | $6.30M | $6.70M | $6.40M | $7.20M |
| QoQ Change | — | +7.7% | +7.1% | +10.0% | +18.2% | +2.6% | -2.5% | +5.1% | +2.4% | +9.5% | +6.5% | +8.2% | +20.8% | -12.5% | +10.7% | +6.5% | -4.5% | +6.3% | -4.5% | +12.5% |
| YoY Change | — | — | — | — | +50.0% | +42.9% | +30.0% | +24.2% | +7.7% | +15.0% | +25.6% | +29.3% | +52.4% | +21.7% | +26.5% | +24.5% | -1.6% | +19.6% | +3.2% | +9.1% |
Range$2.60M – $7.20M
CAGR+23.9%
Avg YoY Growth+23.8%
Median YoY Growth+24.4%
Depreciation at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's depreciation?
- Neurocrine Biosciences (NBIX) reported depreciation of $7.20M in Q1 2026.
- How has Neurocrine Biosciences's depreciation changed year-over-year?
- Neurocrine Biosciences's depreciation increased by 9.1% year-over-year, from $6.60M to $7.20M.
- What is the long-term trend for Neurocrine Biosciences's depreciation?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's depreciation has grown at a 24.3% compound annual growth rate (CAGR), from $10.90M to $26.00M.
- What does depreciation mean?
- The annual expense representing the aging and usage of physical assets.